Related Experiment Video
Updated: Jul 10, 2025
10:26
Assessment of Mitochondrial Health in Cancer-Associated Fibroblasts Isolated from 3D Multicellular Lung Tumor Spheroids
Published on: October 21, 2022
2.0K
High Expression of Fas-Associated Factor 1 Indicates a Poor Prognosis in Non-Small-Cell Lung Cancer
De Hu1, Hidetaka Yamada1, Katsuhiro Yoshimura1,2
1Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Shizuoka, Japan.
Current Oncology (Toronto, Ont.)
|November 24, 2023
Summary
Fas-associated factor 1 (FAF1) overexpression indicates a poor prognosis in non-small-cell lung cancer (NSCLC). This study reveals FAF1 acts as a dangerous factor in NSCLC progression, not an apoptosis promoter.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Fas-associated factor 1 (FAF1) interacts with the Fas death receptor and is implicated in apoptosis.
- FAF1 alterations are noted in various human cancers, but its role in lung cancer remains understudied.
Purpose of the Study:
- To investigate the prognostic value of FAF1 expression in non-small-cell lung cancer (NSCLC).
- To explore the involvement of aberrant FAF1 expression in NSCLC pathogenesis and outcomes.
Main Methods:
- FAF1 expression analysis in NSCLC patient specimens and lung cancer cell lines.
- Assessment of cell viability and apoptosis following FAF1 expression modulation in lung cancer cell lines.
Main Results:
- High FAF1 expression significantly correlates with a poor prognosis in NSCLC patients.
- Downregulation of FAF1 in lung cancer cell lines reduced cell viability and promoted early apoptosis.
Conclusions:
- This is the first study to establish the clinical significance of FAF1 in NSCLC.
- FAF1 overexpression is linked to poor prognosis in NSCLC, functioning as a detrimental factor rather than an apoptosis inducer.
